Cargando…
Precision medicine: Sustained response to erdafitinib in FGFR2 ‐mutant, multiply recurrent ameloblastoma
BACKGROUND: Ameloblastoma imposes significant morbidity and high‐recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined. CASE: We describe a case of a 40‐year‐old male with multiply recurrent, locally inva...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575481/ https://www.ncbi.nlm.nih.gov/pubmed/35761436 http://dx.doi.org/10.1002/cnr2.1656 |